Article | November 10, 2021

Regulatory Forces Drive The Need For Advanced Planning In Study Initiation

Source: Oracle Health Sciences

By Craig Morgan, Head of Marketing, Study Startup, Oracle Health Sciences

iStock-1207691690 PS

Recent regulatory changes establish the need for advanced study planning, aligned study startup management, and cross functional coordination. ICH E8 (R1) and E6 (R3) guidelines will result in a fundamental shift in how all clinical trial regulations are written. Today, regulations are prescriptive and often country-specific, which limits flexibility to implement innovative study designs (e.g., decentralized trials), and often present ambiguities for implementing global studies. Revisions for the ICH E6 (R3) revision are fast approaching, and these guidance’s reconfirm the importance of strategic alignment of eClinical technologies, which ultimately will result in more cost-effective treatment options for patients.

To read more content from Oracle Health Sciences, visit their Clinical Leader page.




Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader